Initial combination therapy with metformin plus Colesevelam in drug-naïve hispanic patients with early type 2 diabetes

Objective: To evaluate initial combination therapy with metformin plus colesevelam in drug-naïve Hispanic patients with type 2 diabetes mellitus. Research Design and Methods: Patients self-identifed as Hispanic from a previous study were included in this exploratory post hoc analysis. Patients were...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2012
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/22849
Acceso en línea:
https://doi.org/10.3810/pgm.2012.07.2560
https://repository.urosario.edu.co/handle/10336/22849
Palabra clave:
Apolipoprotein A1
Apolipoprotein B
Colesevelam
Hemoglobin a1c
Low density lipoprotein cholesterol
Metformin
Placebo
Triacylglycerol
Allylamine
Antidiabetic agent
Cholesterol
Colesevelam
Drug derivative
Glycosylated hemoglobin
Hypocholesterolemic agent
Lipoprotein
Metformin
Abdominal distension
Abdominal pain
Adult
Article
Cholesterol blood level
Cohort analysis
Constipation
Controlled study
Diarrhea
Drug dose titration
Drug efficacy
Drug response
Drug safety
Drug withdrawal
Dyspepsia
Female
Flatulence
Gastritis
Hispanic
Human
Major clinical study
Male
Multicenter study (topic)
Nausea
Non insulin dependent diabetes mellitus
Post hoc analysis
Randomized controlled trial (topic)
Triacylglycerol blood level
Vomiting
Blood
Clinical trial
Controlled clinical trial
Double blind procedure
Drug combination
Ethnology
Hispanic
Randomized controlled trial
Treatment outcome
Allylamine
Anticholesteremic Agents
Cholesterol
Double-Blind Method
Female
Hispanic Americans
Humans
Hypoglycemic Agents
Lipoproteins
Male
Metformin
Treatment Outcome
Bile acid sequestrant
Colesevelam
Hispanic
Metformin
Type 2 diabetes mellitus
Type 2
Combination
Glycosylated
Diabetes Mellitus
Drug Therapy
Hemoglobin A
Rights
License
Abierto (Texto Completo)
id EDOCUR2_7f3541e1ab7a03c74a3de45f97ef42b5
oai_identifier_str oai:repository.urosario.edu.co:10336/22849
network_acronym_str EDOCUR2
network_name_str Repositorio EdocUR - U. Rosario
repository_id_str
spelling 4403950a-3485-404c-9480-053c8a4ed106-1e6f89c9d-8da5-4308-9b33-020e62b46fd6-1ec7eed0b-539a-4ea6-9a42-5a4b3a96c349-146274e04-8cc9-4c10-b28a-f9268538f022-193c4ebbf-6ea9-40c8-81e9-efdd8c81f4a3-1882c9aa6-f061-4398-9c78-3547a5c1d848-12020-05-25T23:58:22Z2020-05-25T23:58:22Z2012Objective: To evaluate initial combination therapy with metformin plus colesevelam in drug-naïve Hispanic patients with type 2 diabetes mellitus. Research Design and Methods: Patients self-identifed as Hispanic from a previous study were included in this exploratory post hoc analysis. Patients were randomized to metformin plus colesevelam or metformin plus placebo. The primary effcacy parameter was the mean change in glycated hemoglobin (HbA1c) levels from baseline. Results: Metformin plus colesevelam had a greater mean HbA1c reduction (-1.2 ± 0.1%) than metformin plus placebo (-0.8 ± 0.1%; P = 0.001) from mean baselines of 7.7% and 7.6%, respectively. Low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol, total cholesterol, and apolipoprotein (apo) B levels were also reduced (P and lt; 0.0001 for all), while triglyceride (P and lt; 0.0001) and apoA-I (P and lt; 0.05) levels were increased with metformin plus colesevelam treatment compared with metformin plus placebo. With metformin plus colesevelam versus metformin plus placebo, more patients achieved an HbA1c of, 7.0% (75% vs 56%) and LDL-C of, 100 mg/dL (49% vs 14%; both P, 0.05). Conclusion: Metformin plus colesevelam may be an effective initial treatment option for Hispanic patients with early type 2 diabetes mellitus. © Postgraduate Medicine.application/pdfhttps://doi.org/10.3810/pgm.2012.07.2560325481https://repository.urosario.edu.co/handle/10336/22849engMedquest Communications LLC13No. 47Postgraduate MedicineVol. 124Postgraduate Medicine, ISSN:325481, Vol.124, No.4 (2012); pp. 7-13https://www.scopus.com/inward/record.uri?eid=2-s2.0-84871672045&doi=10.3810%2fpgm.2012.07.2560&partnerID=40&md5=21be1c7dca5cef8c3cdceae6cbfe21b5Abierto (Texto Completo)http://purl.org/coar/access_right/c_abf2instname:Universidad del Rosarioreponame:Repositorio Institucional EdocURApolipoprotein A1Apolipoprotein BColesevelamHemoglobin a1cLow density lipoprotein cholesterolMetforminPlaceboTriacylglycerolAllylamineAntidiabetic agentCholesterolColesevelamDrug derivativeGlycosylated hemoglobinHypocholesterolemic agentLipoproteinMetforminAbdominal distensionAbdominal painAdultArticleCholesterol blood levelCohort analysisConstipationControlled studyDiarrheaDrug dose titrationDrug efficacyDrug responseDrug safetyDrug withdrawalDyspepsiaFemaleFlatulenceGastritisHispanicHumanMajor clinical studyMaleMulticenter study (topic)NauseaNon insulin dependent diabetes mellitusPost hoc analysisRandomized controlled trial (topic)Triacylglycerol blood levelVomitingBloodClinical trialControlled clinical trialDouble blind procedureDrug combinationEthnologyHispanicRandomized controlled trialTreatment outcomeAllylamineAnticholesteremic AgentsCholesterolDouble-Blind MethodFemaleHispanic AmericansHumansHypoglycemic AgentsLipoproteinsMaleMetforminTreatment OutcomeBile acid sequestrantColesevelamHispanicMetforminType 2 diabetes mellitusType 2CombinationGlycosylatedDiabetes MellitusDrug TherapyHemoglobin AInitial combination therapy with metformin plus Colesevelam in drug-naïve hispanic patients with early type 2 diabetesarticleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Rosenstock, JulioHernandez-Triana, EricHandelsman, YehudaMisir, SoamnauthJones, Michael R.Nagendran, Sukumar10336/22849oai:repository.urosario.edu.co:10336/228492022-05-02 07:37:14.398152https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co
dc.title.spa.fl_str_mv Initial combination therapy with metformin plus Colesevelam in drug-naïve hispanic patients with early type 2 diabetes
title Initial combination therapy with metformin plus Colesevelam in drug-naïve hispanic patients with early type 2 diabetes
spellingShingle Initial combination therapy with metformin plus Colesevelam in drug-naïve hispanic patients with early type 2 diabetes
Apolipoprotein A1
Apolipoprotein B
Colesevelam
Hemoglobin a1c
Low density lipoprotein cholesterol
Metformin
Placebo
Triacylglycerol
Allylamine
Antidiabetic agent
Cholesterol
Colesevelam
Drug derivative
Glycosylated hemoglobin
Hypocholesterolemic agent
Lipoprotein
Metformin
Abdominal distension
Abdominal pain
Adult
Article
Cholesterol blood level
Cohort analysis
Constipation
Controlled study
Diarrhea
Drug dose titration
Drug efficacy
Drug response
Drug safety
Drug withdrawal
Dyspepsia
Female
Flatulence
Gastritis
Hispanic
Human
Major clinical study
Male
Multicenter study (topic)
Nausea
Non insulin dependent diabetes mellitus
Post hoc analysis
Randomized controlled trial (topic)
Triacylglycerol blood level
Vomiting
Blood
Clinical trial
Controlled clinical trial
Double blind procedure
Drug combination
Ethnology
Hispanic
Randomized controlled trial
Treatment outcome
Allylamine
Anticholesteremic Agents
Cholesterol
Double-Blind Method
Female
Hispanic Americans
Humans
Hypoglycemic Agents
Lipoproteins
Male
Metformin
Treatment Outcome
Bile acid sequestrant
Colesevelam
Hispanic
Metformin
Type 2 diabetes mellitus
Type 2
Combination
Glycosylated
Diabetes Mellitus
Drug Therapy
Hemoglobin A
title_short Initial combination therapy with metformin plus Colesevelam in drug-naïve hispanic patients with early type 2 diabetes
title_full Initial combination therapy with metformin plus Colesevelam in drug-naïve hispanic patients with early type 2 diabetes
title_fullStr Initial combination therapy with metformin plus Colesevelam in drug-naïve hispanic patients with early type 2 diabetes
title_full_unstemmed Initial combination therapy with metformin plus Colesevelam in drug-naïve hispanic patients with early type 2 diabetes
title_sort Initial combination therapy with metformin plus Colesevelam in drug-naïve hispanic patients with early type 2 diabetes
dc.subject.keyword.spa.fl_str_mv Apolipoprotein A1
Apolipoprotein B
Colesevelam
Hemoglobin a1c
Low density lipoprotein cholesterol
Metformin
Placebo
Triacylglycerol
Allylamine
Antidiabetic agent
Cholesterol
Colesevelam
Drug derivative
Glycosylated hemoglobin
Hypocholesterolemic agent
Lipoprotein
Metformin
Abdominal distension
Abdominal pain
Adult
Article
Cholesterol blood level
Cohort analysis
Constipation
Controlled study
Diarrhea
Drug dose titration
Drug efficacy
Drug response
Drug safety
Drug withdrawal
Dyspepsia
Female
Flatulence
Gastritis
Hispanic
Human
Major clinical study
Male
Multicenter study (topic)
Nausea
Non insulin dependent diabetes mellitus
Post hoc analysis
Randomized controlled trial (topic)
Triacylglycerol blood level
Vomiting
Blood
Clinical trial
Controlled clinical trial
Double blind procedure
Drug combination
Ethnology
Hispanic
Randomized controlled trial
Treatment outcome
Allylamine
Anticholesteremic Agents
Cholesterol
Double-Blind Method
Female
Hispanic Americans
Humans
Hypoglycemic Agents
Lipoproteins
Male
Metformin
Treatment Outcome
Bile acid sequestrant
Colesevelam
Hispanic
Metformin
Type 2 diabetes mellitus
topic Apolipoprotein A1
Apolipoprotein B
Colesevelam
Hemoglobin a1c
Low density lipoprotein cholesterol
Metformin
Placebo
Triacylglycerol
Allylamine
Antidiabetic agent
Cholesterol
Colesevelam
Drug derivative
Glycosylated hemoglobin
Hypocholesterolemic agent
Lipoprotein
Metformin
Abdominal distension
Abdominal pain
Adult
Article
Cholesterol blood level
Cohort analysis
Constipation
Controlled study
Diarrhea
Drug dose titration
Drug efficacy
Drug response
Drug safety
Drug withdrawal
Dyspepsia
Female
Flatulence
Gastritis
Hispanic
Human
Major clinical study
Male
Multicenter study (topic)
Nausea
Non insulin dependent diabetes mellitus
Post hoc analysis
Randomized controlled trial (topic)
Triacylglycerol blood level
Vomiting
Blood
Clinical trial
Controlled clinical trial
Double blind procedure
Drug combination
Ethnology
Hispanic
Randomized controlled trial
Treatment outcome
Allylamine
Anticholesteremic Agents
Cholesterol
Double-Blind Method
Female
Hispanic Americans
Humans
Hypoglycemic Agents
Lipoproteins
Male
Metformin
Treatment Outcome
Bile acid sequestrant
Colesevelam
Hispanic
Metformin
Type 2 diabetes mellitus
Type 2
Combination
Glycosylated
Diabetes Mellitus
Drug Therapy
Hemoglobin A
dc.subject.keyword.eng.fl_str_mv Type 2
Combination
Glycosylated
Diabetes Mellitus
Drug Therapy
Hemoglobin A
description Objective: To evaluate initial combination therapy with metformin plus colesevelam in drug-naïve Hispanic patients with type 2 diabetes mellitus. Research Design and Methods: Patients self-identifed as Hispanic from a previous study were included in this exploratory post hoc analysis. Patients were randomized to metformin plus colesevelam or metformin plus placebo. The primary effcacy parameter was the mean change in glycated hemoglobin (HbA1c) levels from baseline. Results: Metformin plus colesevelam had a greater mean HbA1c reduction (-1.2 ± 0.1%) than metformin plus placebo (-0.8 ± 0.1%; P = 0.001) from mean baselines of 7.7% and 7.6%, respectively. Low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol, total cholesterol, and apolipoprotein (apo) B levels were also reduced (P and lt; 0.0001 for all), while triglyceride (P and lt; 0.0001) and apoA-I (P and lt; 0.05) levels were increased with metformin plus colesevelam treatment compared with metformin plus placebo. With metformin plus colesevelam versus metformin plus placebo, more patients achieved an HbA1c of, 7.0% (75% vs 56%) and LDL-C of, 100 mg/dL (49% vs 14%; both P, 0.05). Conclusion: Metformin plus colesevelam may be an effective initial treatment option for Hispanic patients with early type 2 diabetes mellitus. © Postgraduate Medicine.
publishDate 2012
dc.date.created.spa.fl_str_mv 2012
dc.date.accessioned.none.fl_str_mv 2020-05-25T23:58:22Z
dc.date.available.none.fl_str_mv 2020-05-25T23:58:22Z
dc.type.eng.fl_str_mv article
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.spa.spa.fl_str_mv Artículo
dc.identifier.doi.none.fl_str_mv https://doi.org/10.3810/pgm.2012.07.2560
dc.identifier.issn.none.fl_str_mv 325481
dc.identifier.uri.none.fl_str_mv https://repository.urosario.edu.co/handle/10336/22849
url https://doi.org/10.3810/pgm.2012.07.2560
https://repository.urosario.edu.co/handle/10336/22849
identifier_str_mv 325481
dc.language.iso.spa.fl_str_mv eng
language eng
dc.relation.citationEndPage.none.fl_str_mv 13
dc.relation.citationIssue.none.fl_str_mv No. 4
dc.relation.citationStartPage.none.fl_str_mv 7
dc.relation.citationTitle.none.fl_str_mv Postgraduate Medicine
dc.relation.citationVolume.none.fl_str_mv Vol. 124
dc.relation.ispartof.spa.fl_str_mv Postgraduate Medicine, ISSN:325481, Vol.124, No.4 (2012); pp. 7-13
dc.relation.uri.spa.fl_str_mv https://www.scopus.com/inward/record.uri?eid=2-s2.0-84871672045&doi=10.3810%2fpgm.2012.07.2560&partnerID=40&md5=21be1c7dca5cef8c3cdceae6cbfe21b5
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.acceso.spa.fl_str_mv Abierto (Texto Completo)
rights_invalid_str_mv Abierto (Texto Completo)
http://purl.org/coar/access_right/c_abf2
dc.format.mimetype.none.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Medquest Communications LLC
institution Universidad del Rosario
dc.source.instname.spa.fl_str_mv instname:Universidad del Rosario
dc.source.reponame.spa.fl_str_mv reponame:Repositorio Institucional EdocUR
repository.name.fl_str_mv Repositorio institucional EdocUR
repository.mail.fl_str_mv edocur@urosario.edu.co
_version_ 1814167570388877312